271 related articles for article (PubMed ID: 22162601)
21. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Moise PA; Smyth DS; El-Fawal N; Robinson DA; Holden PN; Forrest A; Sakoulas G
J Antimicrob Chemother; 2008 Jan; 61(1):85-90. PubMed ID: 18042628
[TBL] [Abstract][Full Text] [Related]
22. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature.
van Hal SJ; Paterson DL; Gosbell IB
Eur J Clin Microbiol Infect Dis; 2011 May; 30(5):603-10. PubMed ID: 21191627
[TBL] [Abstract][Full Text] [Related]
23. The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia.
Honda H; Doern CD; Michael-Dunne W; Warren DK
BMC Infect Dis; 2011 Dec; 11():335. PubMed ID: 22142287
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of methicillin-resistant Staphylococcus aureus bacteremia and comparison of prognosis according to vancomycin MIC values: experience of the last ten years].
Kızılarslanoğlu MC; Sancak B; Yağcı S; Hasçelik G; Unal S
Mikrobiyol Bul; 2013 Apr; 47(2):199-210. PubMed ID: 23621720
[TBL] [Abstract][Full Text] [Related]
25. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.
Holubar M; Meng L; Deresinski S
Infect Dis Clin North Am; 2016 Jun; 30(2):491-507. PubMed ID: 27208769
[TBL] [Abstract][Full Text] [Related]
26. Development of an Amplicon Nanopore Sequencing Strategy for Detection of Mutations Conferring Intermediate Resistance to Vancomycin in Staphylococcus aureus Strains.
Moller AG; Petit RA; Davis MH; Read TD
Microbiol Spectr; 2023 Feb; 11(1):e0272822. PubMed ID: 36688645
[TBL] [Abstract][Full Text] [Related]
27. In vitro activities of daptomycin-, vancomycin-, and teicoplanin-loaded polymethylmethacrylate against methicillin-susceptible, methicillin-resistant, and vancomycin-intermediate strains of Staphylococcus aureus.
Chang Y; Chen WC; Hsieh PH; Chen DW; Lee MS; Shih HN; Ueng SW
Antimicrob Agents Chemother; 2011 Dec; 55(12):5480-4. PubMed ID: 21930872
[TBL] [Abstract][Full Text] [Related]
28. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Soriano A; Marco F; Martínez JA; Pisos E; Almela M; Dimova VP; Alamo D; Ortega M; Lopez J; Mensa J
Clin Infect Dis; 2008 Jan; 46(2):193-200. PubMed ID: 18171250
[TBL] [Abstract][Full Text] [Related]
29. Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA).
Gould IM
Int J Antimicrob Agents; 2013 Jun; 42 Suppl():S17-21. PubMed ID: 23664580
[TBL] [Abstract][Full Text] [Related]
30. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.
Horne KC; Howden BP; Grabsch EA; Graham M; Ward PB; Xie S; Mayall BC; Johnson PD; Grayson ML
Antimicrob Agents Chemother; 2009 Aug; 53(8):3447-52. PubMed ID: 19506056
[TBL] [Abstract][Full Text] [Related]
31. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
[TBL] [Abstract][Full Text] [Related]
32. Emergence of a small colony variant of vancomycin-intermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin.
Lin YT; Tsai JC; Yamamoto T; Chen HJ; Hung WC; Hsueh PR; Teng LJ
J Antimicrob Chemother; 2016 Jul; 71(7):1807-14. PubMed ID: 26968883
[TBL] [Abstract][Full Text] [Related]
33. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
[TBL] [Abstract][Full Text] [Related]
34. Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.
Singh NB; Yim J; Jahanbakhsh S; Sakoulas G; Rybak MJ
Diagn Microbiol Infect Dis; 2018 Aug; 91(4):363-370. PubMed ID: 29807674
[TBL] [Abstract][Full Text] [Related]
35. Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole.
Avery LM; Steed ME; Woodruff AE; Hasan M; Rybak MJ
Antimicrob Agents Chemother; 2012 Nov; 56(11):5990-3. PubMed ID: 22869580
[TBL] [Abstract][Full Text] [Related]
36. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
[TBL] [Abstract][Full Text] [Related]
37. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Kullar R; Davis SL; Kaye KS; Levine DP; Pogue JM; Rybak MJ
Pharmacotherapy; 2013 Jan; 33(1):3-10. PubMed ID: 23307539
[TBL] [Abstract][Full Text] [Related]
38. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
[TBL] [Abstract][Full Text] [Related]
39. High MICs for Vancomycin and Daptomycin and Complicated Catheter-Related Bloodstream Infections with Methicillin-Sensitive Staphylococcus aureus.
San-Juan R; Viedma E; Chaves F; Lalueza A; Fortún J; Loza E; Pujol M; Ardanuy C; Morales I; de Cueto M; Resino-Foz E; Morales-Cartagena A; Rico A; Romero MP; Orellana MÁ; López-Medrano F; Fernández-Ruiz M; Aguado JM
Emerg Infect Dis; 2016 Jun; 22(6):1057-66. PubMed ID: 27192097
[TBL] [Abstract][Full Text] [Related]
40. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.
Cui L; Tominaga E; Neoh HM; Hiramatsu K
Antimicrob Agents Chemother; 2006 Mar; 50(3):1079-82. PubMed ID: 16495273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
